This CPB has been revised to state that denosumab is considered medically necessary for the treatment of bone loss in men with osteoporosis at high-risk for fracture, and for bone metastases from kidney cancer. This CPB is revised to state that denosumab is considered experimental and investigational for the treatment of osteopenia, and hypercalcemia and hyperparathyroidism. This CPB is revised to state that denosumab and intravenous bisphosphonate combination therapy is considered experimental and investigational.